It seems to me Dr Missling is lining all his trial data ducks up for a takeover. That’s what small bios do. Anyone looking for an accelerated approval for any of our indications will continue to be sadly disappointed, IMO. Sitting on the edge of my seat expecting takeoff, defies logic for me now. Missling doesn’t act like someone gearing up for commercialization. He will do very well with a takeover. I hope shareholders do as well.